吉非替尼治疗晚期非小细胞肺癌7例临床观察  

Clinical observation of gefitinib as the treatment for patients with advanced stage non-small cell lung cancer

作　　者：孟春[1] 曲卓慧[1] 翟凤岐[1] 

机构地区：[1]吉林省四平市中心医院肿瘤科,136000

出　　处：《中国实用医药》2009年第2期146-147,共2页China Practical Medicine

摘　　要：目的观察吉非替尼治疗晚期非小细胞肺癌临床疗效及毒副反应。方法研究2006年6月至2007年11月晚期非小细胞肺癌患者口服吉非替尼治疗,250mg/d,观察其近期疗效及毒副反应。结果7例患者中CR0%(0/7)、PR57.1%(4/7)、SD28.6%(2/7)、PD14.3%(1/7)、临床获益率(CR+PR+SD)85.7%。毒副反应为唑疮样皮疹85.7%(6/7)、腹泻42.9%(3/7)、转氨酶升高14.3%(1/7)、急性间质性肺病14.3%(1/7)。结论吉非替尼治疗晚期非小细胞肺癌疗效较好,毒副反应轻微,临床获益率高,能明显改善患者的生活质量。Objective To evaluate the response and the side effects of gefitinib as the treatment in pa- tients with advanced non-small cell lung cancer. Methods Totally 7 non-small cell lung cancer patients,treated from June 2006 to November 2007,were enrolled in our study Gefitinib was prescribed on the oral dose of 250 mg daily. The treatment response and side-effects were recorded. Results CR, PR, SD, PD were achieved 0% （0/7）, 57.1% （4/7） , 28.6% （ 2/7 ） and 14. 3 % （ 1/7 ）, respectively. Symptom improvement was reported by 85.7%. Adverse events included acneiform rash 85.7% （ 6/7 ）, diarrhea 42. 9% （ 3/7 ） , hepatic dysfunction 14. 3% （ 1/7 ） and acute interstitial lung disease 14. 3% （ 1/7 ）. Conclusion Gefitinib is an effective therapy for patients with advanced non-small cell lung cancer with acceptable side effects.

关 键 词：吉非替尼 晚期非小细胞肺癌 临床分析 疗效 

分 类 号：R734.2[医药卫生—肿瘤]